

Supplementary Figure 1. Information component values of drug-induced liver injury with ritonavir-boosted nirmatrelvir vs other COVID drugs used under emergency use authorization. Sensitivity analysis was conducted by restricting the data to those reported by healthcare professionals only. AEs, adverse events; DILI, drug-induced liver injury.

DILI of	Total AEs of	DILI of other	Total AEs of other
Nirmatrelvir	Nirmatrelvir	COVID drugs	COVID drugs

Information component (95% CI)



-2

0

2